Search - Leibniz Institute for Prevention Research and Epidemiology

301. [BIPS Project] PASS to evaluate cardiovascular events in adult patients with obstructive sleep apnoe (OSA) treated with solriamfetol

URL: /en/research/projects/detail-view.html?projID=939&cHash=1c6fc18afaf3d549b79439bd5e94158a
Date: 15-06-22

Obstructive sleep apnea (OSA) is characterized by sleep fragmentation due to short-term oxygen deprivation caused by upper airway obstruction. A major symptom of OSA is excessive daytime sleepiness,…

302. [BIPS Project] Pharmacoepidemiological safety study of neuroleptics and antidepressants in the area of geriatric psychiatrics

URL: /en/research/projects/detail-view.html?projID=476&cHash=2613c1f6f9a8f2ef0c8cc0c397ee5124
Date: 01-11-12

More than half of Germans aged 65 and older are treated with antipsychotics or antidepressants despite of concerns that the use of these drugs in this population is associated with an increase in…

303. [BIPS Project] Physical activity and health equity: primary prevention for healthy ageing

URL: /en/research/projects/detail-view.html?projID=712&cHash=fff020aec32e7f3697dc868eee038068
Date: 01-02-18

AEQUIPA: Physical activity and health equity: primary prevention for healthy ageing AEQUIPA is a regional prevention research network comprising six universities, two research institutes and the…

304. [BIPS Project] Pilot project for the cross-sectoral implementation of a comprehensive and quality-tested sports and exercise therapy for cancer

URL: /en/research/projects/detail-view.html?projID=964&cHash=f8145541a2c5c50f087758bbfee9fdd4
Date: 01-03-23

IMPLEMENT aims to develop, test and establish a sustainable access structure for quality-assured oncological exercise therapy in Germany as a model within the funding period of three years. In the…

305. [BIPS Project] Policy evaluation network - Public policies addressing health-related behaviours in Europe

URL: /en/research/projects/detail-view.html?projID=740&cHash=9352f80adcf9237e1653479c9373a2f8
Date: 01-02-19

Non-communicable diseases (NCDs) are the leading cause of global mortality, responsible for 41 million deaths each year. Successful policy actions to address physical inactivity, unhealthy diets, and…

306. [BIPS Project] Pooled analysis of European case-control studies on the interaction of occupational carcinogens in the development of lung cancer

URL: /en/research/projects/detail-view.html?projID=255&cHash=9467fe697f13e1339ae60e26527d392f
Date: 01-04-07

The SYNERGY project -a pooled analysis of case-control studies on the joint effects of occupational carcinogens in the development of lung cancer- began in January 2007. The aim of SYNERGY is to…

307. [BIPS Project] Post-authorisation safety study of nocdurna for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria: A multi-country cohort study using secondary data

URL: /en/research/projects/detail-view.html?projID=917&cHash=f3708b280935a2f6fdb046a4bcf0808f
Date: 17-11-20

Nocdurna (desmopressin) has been approved in Germany since January 2017 for the treatment of nocturia in adult patients with idiopathic nocturnal polyuria. Desmopressin is an analog of the…

308. [BIPS Project] Post-authorisation safety study of tralokinumab use in pregnancy

URL: /en/research/projects/detail-view.html?projID=1040&cHash=61d281ea60f3f02b443b69dfb3b9577a
Date: 01-01-23

Tralokinumab is a biological agent developed for the treatment of moderate to severe atopic dermatitis (AD) and is administered by subcutaneous injection. Tralokinumab is a fully human immunoglobulin…

309. [BIPS Project] Post-authorization safety study on agomelatine and the risk of hospitalization for acute liver injury

URL: /en/research/projects/detail-view.html?projID=614&cHash=d6fb320a906b37e1962b34f47eea3ffd
Date: 15-08-14

Agomelatine (Valdoxan, Thymanax) is a melatonergic agonist and 5-HT2C antagonist which is, among other antidepressants, indicated for major depressive episodes in adults. Its marketing authorisation…

310. [BIPS Project] Post-marketing drug utilization study for galcanezumab

URL: /en/research/projects/detail-view.html?projID=827&cHash=69f47eb761baaa0a1cab27c240e33036
Date: 01-03-19

Galcanezumab is a humanised monoclonal antibody against human calcitonin gene-related peptide and is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month…